Skip to main content
Clinical Trials/NCT06305949
NCT06305949
Recruiting
Not Applicable

A Multi-center, Randomized, Double-blind, Pilot Study to Evaluate the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Transitory Improvement of Swallowing Function in Patients With Post-stroke Dysphagia

NEUROPHET2 sites in 1 country30 target enrollmentApril 22, 2024

Overview

Phase
Not Applicable
Intervention
Optimized transcranial Direct Current Stimulation
Conditions
Deglutition Disorders
Sponsor
NEUROPHET
Enrollment
30
Locations
2
Primary Endpoint
Penetration-aspiration Scale (PAS)
Status
Recruiting
Last Updated
23 days ago

Overview

Brief Summary

The goal of this clinical trial is to evaluate whether the application of optimized transcranial direct current stimulation is more effective compared to sham stimulation for temporary improvement of swallowing function in patients with post-stroke dysphagia.

Registry
clinicaltrials.gov
Start Date
April 22, 2024
End Date
June 30, 2026
Last Updated
23 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
NEUROPHET
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • men and women \>19 years old
  • patients with stroke confirmed by neuroimaging
  • first-time stroke patients
  • patients in subacute or chronic phases of stroke with 3 weeks or more after onset
  • stroke patients with confirmed dysphagia through Videofluoroscopic Swallowing Study (VFSS).

Exclusion Criteria

  • patients with recurrent stoke, traumatic brain injury, spine cord injury, and degenerative brain disease, such as Parkinson's disease, etc.
  • patients with deteriorated cognitive function unable to perform the clinical trial as instructed
  • patients with evidence of delirium, confusion, or other impairment of consciousness
  • patients with uncontrolled medical disease or surgical conditions
  • patients ineligible for Transcranial direct current stimulation (due to scalp condition, metallic material at the electrode attachment area, presence of a pacemaker or cochlear implant)
  • patients with previous experience within the last year using a stimulation device similar to the one use in this clinical trial or who have participated in related clinical trials
  • patients with severe neurologic disorder with concomitant major psychiatric disorder such as major depressive disorder and dementia
  • patients with history of uncontrolled epilepsy within 6 months
  • patients with medical contraindications for neuroimaging test, such as MRI;
  • patients who are taken contraindicated medications or require medication changes during the trial period that could influence cognitive/motor function changes via brain activation changes

Arms & Interventions

Optimized transcranial Direct Current Stimulation

Patients receive optimized stimulation obtained from an individualized T1 MRI-based simulation of transcranial direct current stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.

Intervention: Optimized transcranial Direct Current Stimulation

Sham transcranial Direct Current Stimulation

Patients receive sham stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.

Intervention: Sham transcranial Direct Current Stimulation

Outcomes

Primary Outcomes

Penetration-aspiration Scale (PAS)

Time Frame: Baseline, At 4 weeks from baseline

PAS is a standard scale to assess deglutition in clinical practice and research. It is composed of an 8-point scale used to characterize both the location of airway invasion events and patient's response during video fluoroscopic swallowing studies. The scale design to capture three constructs: depth of airway invasion, material remaining after swallow, and patient's response to aspiration. The scale ranges from score 1 (Material does not enter the airway) to score 8 (Material enters the airway, passes below the level of the vocal folds, and no effort is made to eject)

Functional Oral Intake Scale (FOIS)

Time Frame: Baseline, At 4 weeks from baseline

FOIS is a scale used for purposes to assess changes in functional oral intake of food and liquids in patients with dysphagia. FOIS is sensitive to changes in oral intake of food and liquid over time in stroke patients. The scale ranges from level 1 (nothing by mouth) to level 7 (a full unrestricted oral diet)

Secondary Outcomes

  • Penetration-aspiration Scale (PAS)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Korean Mann Assessment of Swallowing Ability (K-MASA)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Gugging Swallowing Screen(Baseline, At 2, 4, and 8 weeks from baseline)
  • Motor-Evoked Potential (MEP)(Baseline, At 2 and 4 weeks from baseline)
  • Peak cough flow(Baseline, At 4, and 8 weeks from baseline)
  • Functional Oral Intake Scale (FOIS)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Videofluoroscopic Dysphagia Scale (VDS)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Grade, Roughness, Breathiness, Asthenia and Strain scale(GRBAS scale)(Baseline, At 4, and 8 weeks from baseline)
  • Respiratory muscle strength(Baseline, At 4, and 8 weeks from baseline)
  • Urimal Test of Articulation and Phonology (U-TAP)(Baseline, At 4, and 8 weeks from baseline)
  • modified Rankin Scale (mRS)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Eating Assessment Tool-10 (EAT-10)(Baseline, At 2, 4, and 8 weeks from baseline)
  • Speech Mechanism Screening Test (SMST)(Baseline, At 4, and 8 weeks from baseline)
  • Iowa Oral Performance Instrument (IOPI)(Baseline, At 4, and 8 weeks from baseline)

Study Sites (2)

Loading locations...

Similar Trials